Evidence map›Paper›PMID 20629771›Full record

ArticleInfluenza and other respiratory viruses2010

Protective effect of single-dose adjuvanted pandemic influenza vaccine in children.

P G Van Buynder, J K Dhaliwal, J L Van Buynder, C Couturier, M Minville-Leblanc, R Garceau, F-W Tremblay

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Influenza and other respiratory viruses, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 7 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 7 syntheses or guidelines pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Vaccines for preventing influenza in healthy children.The Cochrane database of systematic reviews · 2018
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Vaccines for preventing influenza in healthy children.The Cochrane database of systematic reviews · 2012
    Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Review
  13. Review
  14. From discovery to licensure, the Adjuvant System story.Human vaccines & immunotherapeutics · 2017
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

P G Van BuynderNew Brunswick Department of Health, Office of the Chief Medical Officer of Health (OCMOH), Fredericton, NB, Canada. pjvb@iinet.net.au
J K Dhaliwal
J L Van Buynder
C Couturier
M Minville-Leblanc
R Garceau
F-W Tremblay
Government of New Brunswick · CADr. Georges-L.-Dumont University Hospital Centre · CAThe University of Western Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDuring the first wave of A/California/7/2009(H1N1) influenza, high rates of hospitalization in children under 5 years were seen in many countries. Subsequent policies for vaccinating children varied in both type of vaccine and number of doses. In Canada, children 36 months to <10 years received a single dose of 0.25 ml of the GSK adjuvanted vaccine (Arepanrix) equivalent to 1.9 microg HA. Children 6 months to 35 months received two doses as did those 36-119 months with chronic medical conditions.

methodWe conducted a community-based case-control vaccine effectiveness (VE) review of children under 10 years with influenza like illness who were tested for H1N1 infection at the central provincial laboratory. Laboratory-confirmed influenza was the primary outcome, and vaccination status the primary exposure to assess VE after a single 0.25-ml dose.

resultsIf vaccination was designated to be effective after 14 days, no vaccinated child had laboratory-confirmed influenza compared to 38% of controls. The VE of 100% was statistically significant for children <10 years of age and <5 years considered separately. If vaccination was considered effective after 10 days, VE dropped to 96% overall but was statistically significant and over 90% in all age subgroups, including those under 36 months.

conclusionsA single 0.25-ml dose of the GSK adjuvanted vaccine (Arepanrix) protects children against laboratory-confirmed pandemic influenza potentially avoiding any increased reactogenicity associated with second doses. Adjuvanted vaccines offer hope for improved seasonal vaccines in the future.

Indexed as

Adjuvants, ImmunologicCanadaCase-Control StudiesChildChild, PreschoolDisease OutbreaksFemaleHumansImmunization ScheduleInfantInfluenza A Virus, H1N1 SubtypeInfluenza, HumanInfluenza VaccinesMalePandemicsTreatment OutcomeAdjuvants, ImmunologicInfluenza Vaccines

Identifiers

PMID20629771
PMCPMC5964543
OpenAlexW1588310307

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.